Cargando…

RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines

Ras-specific proteases to degrade RAS within cancer cells are under active development as an innovative strategy to treat tumorigenesis. The naturally occurring biological toxin effector called RAS/RAP1-specific endopeptidase (RRSP) is known to cleave all RAS within a cell, including HRAS, KRAS, NRA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stubbs, Caleb K., Biancucci, Marco, Vidimar, Vania, Satchell, Karla J. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429734/ https://www.ncbi.nlm.nih.gov/pubmed/34504197 http://dx.doi.org/10.1038/s41598-021-97422-0

Ejemplares similares

Delivering a RAS protease halts tumor growth
por: Vidimar, Vania, et al.
Publicado: (2020)

A bacterial toxin that cleaves Ras oncoprotein
por: Biancucci, Marco, et al.
Publicado: (2015)

Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain
por: Antic, Irena, et al.
Publicado: (2015)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)

SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status
por: Song, Ha Yong, et al.
Publicado: (2016)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Genome-wide DNA methylation analysis of KRAS mutant cell lines
por: Tew, Ben Yi, et al.
Publicado: (2020)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
por: Park, Sujeong, et al.
Publicado: (2018)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
por: Luo, Lian-Xiang, et al.
Publicado: (2017)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Co-dependency of PKCδ and K-Ras: Inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer
por: Ohm, Angela M., et al.
Publicado: (2017)

A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers
por: Cheng, Rongjie, et al.
Publicado: (2022)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
por: Hiraki, Masayuki, et al.
Publicado: (2015)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
por: Alves, Sara, et al.
Publicado: (2015)

MICA (∗)012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
por: Ding, Weifeng, et al.
Publicado: (2020)

Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer
por: Liu, Huashan, et al.
Publicado: (2021)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Cordyceps militaris Grown on Germinated Soybean Suppresses KRAS-Driven Colorectal Cancer by Inhibiting the RAS/ERK Pathway
por: Seo, HeeJung, et al.
Publicado: (2018)

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
por: Kopreski, M. S., et al.
Publicado: (1997)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Rab13 regulates sEV secretion in mutant KRAS colorectal cancer cells
por: Hinger, Scott A., et al.
Publicado: (2020)

Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas
por: Gao, WenChao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2k5i3rj7evmb7n6sfbbi8p8au4